Radiopharm Theranostics Limited (ASX:RAD)
Australia
· Delayed Price · Currency is AUD 0.0210
0.00 (0.00%)
At close: Mar 6, 2026
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
16.28M
Revenue Growth
+4,823.49%
P/S Ratio
4.57
Revenue / Employee
1.16M
Employees
14
Market Cap
74.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Imugene | 3.94M |
| LTR Pharma | 1.13M |
| Cynata Therapeutics | 1.69M |
| Alterity Therapeutics | 6.64M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
Radiopharm Theranostics News
- 5 weeks ago - Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - RAD Increases Ownership in Radiopharm Ventures to 87.5% - GlobeNewsWire
- 2 months ago - Why Is Radiopharm Theranostics Stock Rallying Over 140%? - Benzinga
- 2 months ago - Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - GlobeNewsWire
- 3 months ago - Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News - GuruFocus
- 4 months ago - Lantheus (LNTH) Commits to Significant Investment in Radiopharm Theranostics - GuruFocus
- 4 months ago - Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan - GlobeNewsWire
- 5 months ago - Regal-backed biotech Radiopharm Theranostics launches $35m placement - The Australian Financial Review